clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Matsumoto T et al. Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori. 1997 Lancet pmid:9228971
Kadayifçi A et al. Clarithromycin-induced fever in a patient with Helicobacter pylori gastritis. 1997 Ann Pharmacother pmid:9184727
Taylor DE et al. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. 1997 Antimicrob. Agents Chemother. pmid:9420030
Götz JM et al. Treatment of Helicobacter pylori infection favourably affects gastric mucosal superoxide dismutases. 1997 Gut pmid:9203935
Verhaegen J et al. Impredictable susceptibility for cephalosporins in penicillin resistant Streptococcus pneumoniae. 1997 Acta Clin Belg pmid:9204588
Kim MJ et al. Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment. 1997 Gastroenterology pmid:9207259
Gotoh A et al. Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. 1997 Microbiol. Immunol. pmid:9087962
Driscoll MS and Tyring SK Development of resistance to clarithromycin after treatment of cutaneous Mycobacterium chelonae infection. 1997 J. Am. Acad. Dermatol. pmid:9091495
Gui GP et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. 1997 J. Antimicrob. Chemother. pmid:9096189
Hoogkamp-Korstanje JA et al. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. 1997 J. Antimicrob. Chemother. pmid:9096192
Fietta A et al. Inhibition of intracellular growth of Staphylococcus aureus by exposure of infected human monocytes to clarithromycin and azithromycin. 1997 J Chemother pmid:9106013
Lazzaroni M et al. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. 1997 Am. J. Gastroenterol. pmid:9128316
Díaz F et al. [Cat-scratch disease. A report of 4 cases and a review of the literature]. 1997 Rev Clin Esp pmid:9102668
Szczebara F et al. Evaluation of rapid molecular methods for detection of clarithromycin resistance in Helicobacter pylori. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9105846
Arguedas A et al. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. 1997 J Chemother pmid:9106017
Horgen L et al. Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. 1997 Res. Microbiol. pmid:9765852
Denys A [Theoretical basis for the antibiotic therapy of the upper part of the respiratory system]. 1997 Otolaryngol Pol pmid:9757681
Pendland SL et al. Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones. 1997 J. Clin. Microbiol. pmid:9350781
Kubas G and Gospodarek T [The use of clarithromycin and amoxycillin in pediatric acute otitis media]. 1997 Otolaryngol Pol pmid:9757683
Suzuki K et al. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages. 1997 Int. J. Tuberc. Lung Dis. pmid:9441102
Axon AT et al. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9042977
Gotoh A et al. Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori. 1997 Microbiol. Immunol. pmid:9444328
Labenz J et al. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. 1997 Aliment. Pharmacol. Ther. pmid:9042978
Labenz J et al. Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. 1997 Aliment. Pharmacol. Ther. pmid:9042979
Prattichizzo FA et al. [Carditis associated with Mycoplasma pneumoniae infection. Clinical aspects and therapeutic problems]. 1997 Minerva Cardioangiol pmid:9446067
Erah PO et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. 1997 J. Antimicrob. Chemother. pmid:9044021
Genné D et al. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9447898
Roche B et al. Efficacy of combined clarithromycin and sparfloxacin therapy in a patient with discitis: due to Mycobacterium xenopi. 1997 Rev Rhum Engl Ed pmid:9051864
Ridgway GL et al. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. 1997 J. Antimicrob. Chemother. pmid:9484871
Goh KL et al. Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? 1997 Aliment. Pharmacol. Ther. pmid:9663838
Kolkman JJ et al. Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9663840
Miyaji H et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. 1997 Aliment. Pharmacol. Ther. pmid:9663841
Greco S et al. Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics. 1997 Ann Pharmacother pmid:9416400
Buckley MJ et al. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. 1997 Dig. Dis. Sci. pmid:9365144
Dautzenberg B Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease. 1997 Drugs pmid:9358194
Misiewicz JJ et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. 1997 Gut pmid:9462204
Cohn DL Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS. 1997 Drugs pmid:9358195
Loo VG et al. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. 1997 J. Antimicrob. Chemother. pmid:9462442
Hoffner SE et al. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. 1997 J. Antimicrob. Chemother. pmid:9462443
Torresani C et al. Clarithromycin versus doxycycline in the treatment of rosacea. 1997 Int. J. Dermatol. pmid:9466207
Tzivras M et al. One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. 1997 Eur J Gastroenterol Hepatol pmid:9471024
Kawasaki M et al. Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. 1997 Am. J. Gastroenterol. pmid:9382064
Adamek RJ et al. Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection. 1997 Am. J. Gastroenterol. pmid:9382084
Konishi T and Nakao M Antibiotic treatment in mice infected with Japanese Borrelia garinii: efficacy of ceftriaxone for eradicating the infection induced by Ixodes persulcatus tick bites. 1997 Microbiol. Immunol. pmid:9087959
García-de-Lomas J et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolated from pediatric carriers in Spain. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9063666
Weiss I et al. Serotyping and susceptibility to macrolides and other antimicrobial drugs of Streptococcus pyogenes isolated from patients with invasive diseases in southern Israel. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9063669
Cammarota G et al. Regression of a primary gastric MALT lymphoma with extensive antrum lesions by Helicobacter pylori eradication. 1997 Ital J Gastroenterol Hepatol pmid:9476192
Hotz J [Reflux disease of the gastrointestinal tract. Acute therapy and long-term care in daily practice. 2. Therapeutic procedure--diagnosis--therapy-diagram]. 1997 Fortschr. Med. pmid:9480263
Thornsberry C et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. 1997 Diagn. Microbiol. Infect. Dis. pmid:9458982
Briant C et al. Pericarditis as a manifestation of Lyme disease. 1997 J Emerg Nurs pmid:9460386
Feldman C et al. Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. 1997 Inflammation pmid:9429912
Lévy M et al. Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically. 1997 Gastrointest. Endosc. pmid:9351036
Misiewicz JJ Management of Helicobacter pylori-related disorders. 1997 Eur J Gastroenterol Hepatol pmid:9160212
Hultén K et al. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. 1997 Antimicrob. Agents Chemother. pmid:9371366
Barry AL et al. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9405952
Mitsuyama T et al. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. 1997 Int. Arch. Allergy Immunol. pmid:9338603
Hirakawa T [Diagnosis and treatment of Helicobacter pylori]. 1997 Nippon Ika Daigaku Zasshi pmid:9283206
Meyer JM et al. In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. 1997 Antimicrob. Agents Chemother. pmid:9210696
Chimura T [Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection]. 1997 Jpn J Antibiot pmid:9212369
Lim AG et al. Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. 1997 Aliment. Pharmacol. Ther. pmid:9218079
Laine L et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. 1997 Am. J. Gastroenterol. pmid:9399755
Midolo PD et al. Antimicrobial resistance testing of Helicobacter pylori: a comparison of Etest and disk diffusion methods. 1997 Pathology pmid:9423225
Srinivasan R and Minocha A Cure of Helicobacter pylori: a hidden curse? 1997 Am. J. Gastroenterol. pmid:9399784
Sekkarie MA Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. 1997 Am. J. Kidney Dis. pmid:9292575
Akaki T et al. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice]. 1997 Kekkaku pmid:9293712
Recker MW and Kier KL Potential interaction between clarithromycin and warfarin. 1997 Ann Pharmacother pmid:9296238
Phull PS et al. Lansoprazole plus clarithromycin: evaluation of a new dual therapy for Helicobacter pylori eradication. 1996 Oct-Nov Br J Clin Pract pmid:9015906
Peeling RW and Brunham RC Chlamydiae as pathogens: new species and new issues. 1996 Oct-Dec Emerging Infect. Dis. pmid:8969247
Prescott LM Clarithromycin for MAC prevention offers additional benefits. 1996 May-Jun Posit Aware pmid:11363431
Mertl SL The role of clarithromycin in the prophylaxis of disseminated Mycobacterium avium-intracellulare infection in patients with AIDS. 1996 May-Jun Pharmacotherapy pmid:8726597
Ono T et al. In vitro and in vivo antibacterial activities of clarithromycin. 1996 May-Jun Chemotherapy pmid:8983882
Nightingale SL From the Food and Drug Administration. 1996 May 22-29 JAMA pmid:8622234
Sketris IS et al. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction. 1996 Mar-Apr Pharmacotherapy pmid:8820476
Akamatsu H et al. Enhanced effect of clarithromycin on neutrophil function in vitro. 1996 Mar-Apr J. Int. Med. Res. pmid:8737228
Papp J et al. Efficacy of nizatidine, clarithromycin and bismuth subcitrate therapy for Helicobacter pylori eradication in duodenal ulcer patients--a preliminary report. 1996 Jul-Aug Br J Clin Pract pmid:8794601
Tursi A et al. One-week low-dose triple therapy vs. two-week medium-dose double therapy for H.pylori infection. 1996 Jul-Aug Hepatogastroenterology pmid:8884304
Amsden GW Erythromycin, clarithromycin, and azithromycin: are the differences real? 1996 Jan-Feb Clin Ther pmid:8851453
Sander P et al. Ribosomal drug resistance in mycobacteria. 1996 Jan-Feb Res. Microbiol. pmid:8761724
Berg-Candolfi M and Candolfi E Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection. 1996 Int. J. Parasitol. pmid:9024879
Griffith DE et al. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. 1996 Clin. Infect. Dis. pmid:8953085
Bates JH Mycobacterium avium disease: progress at last. 1996 Am. J. Respir. Crit. Care Med. pmid:8665029
Wallace RJ et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. 1996 Am. J. Respir. Crit. Care Med. pmid:8665032
Frothingham R Clarithromycin treatment for Mycobacterium avium-intracellulare complex lung disease. 1996 Am. J. Respir. Crit. Care Med. pmid:8665069
Tsuyuguchi K [In vitro anti-MAC activities of new quinolones in focus (1)]. 1996 Kekkaku pmid:8999136
Sakatani M [Pilot studies on the treatment of Mycobacterium avium complex lung disease--new macrolides and new quinolones. (1) Continuous positive cases (failure of the initial chemotherapy)]. 1996 Kekkaku pmid:8999139
Tanaka E [Pilot studies on the treatment of Mycobacterium avium complex lung disease--new macrolides and new quinolones. (2) Multi-drug chemotherapy for initial cases on trial]. 1996 Kekkaku pmid:8999140
Aoyama T et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. 1996 J. Pediatr. pmid:8917247
Chiba N Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. 1996 Am. J. Gastroenterol. pmid:8855737
Engelhardt E et al. [Postoperative infection with Mycobacterium chelonae]. 1996 Hautarzt pmid:9036143
Labenz J et al. [Ulcer healing through the elimination of Helicobacter pylori: is a week of therapy enough?]. 1996 Dtsch. Med. Wochenschr. pmid:8565802
Goh KL et al. Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy. 1996 Eur J Gastroenterol Hepatol pmid:8804868
Flamm RK et al. Kill kinetics of antimicrobial agents against Helicobacter pylori. 1996 J. Antimicrob. Chemother. pmid:8937967
Bermudez LE et al. Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model. 1996 J. Infect. Dis. pmid:8940212
Nagashima R et al. Regression of duodenal mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. 1996 Gastroenterology pmid:8942749
Gross U and Pohl F Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii. 1996 Curr. Top. Microbiol. Immunol. pmid:8791704
Peterson WL et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. 1996 Aliment. Pharmacol. Ther. pmid:8791947
Delchier JC et al. Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. 1996 Aliment. Pharmacol. Ther. pmid:8791948
Harris AW et al. Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. 1996 Aliment. Pharmacol. Ther. pmid:8971302
Moshkowitz M et al. One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. 1996 Aliment. Pharmacol. Ther. pmid:8971304
Laine L et al. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. 1996 Aliment. Pharmacol. Ther. pmid:8971306